Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
Heparin Market: By Product, Ultra-low Molecular Weight Heparin, By Application, By Distribution Channel and Geography
Heparin Market size was valued at US$ 7,923.7 million in 2023 and is projected to grow at a 2.8% CAGR from 2024 to 2030. Heparin is a naturally occurring glycosaminoglycan, also known as unfractionated heparin (UFH). It is used in medicine as an anticoagulant (blood thinner). It is especially beneficial in the treatment of heart attacks and unstable angina. It is injected into a vein or beneath the skin. Acute coronary syndrome, deep vein thrombosis, pulmonary embolism, and atrial fibrillation are all treated with it, as are cardiopulmonary bypass and hemofiltration during cardiac surgery. It also administers major orthopedic procedures like hip and knee replacements.
Based on the product, the global market is segmented into Unfractionated Heparin, Low Molecular Weight Heparin (LMWH), and Ultra-low Molecular Weight Heparin (ULMWH). The Low Molecular Weight Heparin (LMWH) segment is anticipated to grow at a significant CAGR over the forecast years. Longer and more predictable operation than UFH, as well as easy self-administration at home via subcutaneous injection, which reduces or eliminates hospital stays and eliminates the need for daily blood monitoring, are all important factors driving the market growth. Factors such as increasing advantages of low molecular weight heparin over unfractionated heparin and increasing introduction of biosimilar low molecular weight heparin anticoagulants globally are expected to drive the market growth.
Study Period
2024-2030Base Year
2023CAGR
2.8%Largest Market
Asia PacificFastest Growing Market
North America
The rise in the prevalence of cardiovascular diseases in key age groups, such as the geriatric population, which is expected to fuel demand for this product, is one of the primary driving factors influencing the global market. Most diseases, including heart attacks, strokes, venous thromboembolism, and cardiovascular conditions like atrial fibrillation, are expected to remain common in the coming years. According to the Centers for Disease Control and Prevention (CDC), approximately 655,000 Americans will die from cardiovascular diseases in 2020. Furthermore, according to 2017 statistics, 18.2 million adults aged 20 and up have coronary artery disease. Such trends and statistics represent significant potential and existing patient populations worldwide; these are just a few factors contributing to the high demand for these products. Furthermore, increasing patient awareness of these drugs' efficacy in treating various heart diseases will drive the market. Due to which, the rising prevalence and incidence of cardiovascular diseases will drive market growth over the forecast period.
Report Benchmarks |
Details |
Report Study Period |
2024-2030 |
Market Size in 2023 |
US$ 7,923.7 million |
Market CAGR |
2.8% |
By Product Type |
|
By Application |
|
By Distribution Channel |
|
By Region |
|
Download Free Sample Report
The global heparin market size was valued at US$ 7,923.7 million in 2023 and is projected to grow at a 2.8% CAGR from 2024 to 2030.
The market key players are: Baxter International Inc. B. Braun Holding GmbH & Co. KG Dr Reddy's Laboratories Ltd. Fresenius SE & Co KGaA Hebei Changshan Biochemical Pharmaceutical Co., Ltd. Leo Pharma A/S Pfizer Inc. Sanofi SA Teva Pharmaceuticals Viatris Inc.
The market has been classified into North America, Asia Pacific, Europe, Latin America, Middle East and Africa, and the rest of MEA.
1. Executive Summary |
2. Global Heparin Market Introduction |
2.1.Global Heparin Market - Taxonomy |
2.2.Global Heparin Market - Definitions |
2.2.1.Product Type |
2.2.2.Application |
2.2.3.Distribution Channel |
2.2.4.Geography |
2.2.5.Region |
3. Global Heparin Market Dynamics |
3.1. Drivers |
3.2. Restraints |
3.3. Opportunities/Unmet Needs of the Market |
3.4. Trends |
3.5. Product Landscape |
3.6. New Product Launches |
3.7. Impact of COVID 19 on Market |
4. Global Heparin Market Analysis, 2019-2023 and Forecast 2024-2030 |
4.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
4.3. Market Opportunity Analysis |
5. Global Heparin Market By Product Type, 2019-2023 and Forecast 2024-2030 (Sales Value USD Million) |
5.1. Unfractionated Heparin |
5.1.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.3. Market Opportunity Analysis |
5.2. Low Molecular Weight Heparin (LMWH) |
5.2.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.3. Market Opportunity Analysis |
5.3. Ultra-low Molecular Weight Heparin (ULMWH) |
5.3.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.3.3. Market Opportunity Analysis |
6. Global Heparin Market By Application, 2019-2023 and Forecast 2024-2030 (Sales Value USD Million) |
6.1. Venous Thromboembolism |
6.1.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.1.3. Market Opportunity Analysis |
6.2. Coronary Artery Disease |
6.2.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.2.3. Market Opportunity Analysis |
6.3. Atrial Fibrillation |
6.3.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.3.3. Market Opportunity Analysis |
6.4. Others |
6.4.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.4.3. Market Opportunity Analysis |
7. Global Heparin Market By Distribution Channel , 2019-2023 and Forecast 2024-2030 (Sales Value USD Million) |
7.1. Hospital Pharmacies |
7.1.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.1.3. Market Opportunity Analysis |
7.2. Drug Stores & Retail Pharmacies |
7.2.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.2.3. Market Opportunity Analysis |
7.3. Online Pharmacies |
7.3.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.3.3. Market Opportunity Analysis |
8. Global Heparin Market By Geography, 2019-2023 and Forecast 2024-2030 (Sales Value USD Million) |
8.1. North America |
8.1.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.1.3. Market Opportunity Analysis |
8.2. Europe |
8.2.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.2.3. Market Opportunity Analysis |
8.3. The Asia Pacific |
8.3.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.3.3. Market Opportunity Analysis |
8.4. Latin America |
8.4.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.4.3. Market Opportunity Analysis |
8.5. MEA |
8.5.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.5.3. Market Opportunity Analysis |
9. Global Heparin Market By Region, 2019-2023 and Forecast 2024-2030 (Sales Value USD Million) |
9.1. North America |
9.1.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
9.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.1.3. Market Opportunity Analysis |
9.2. Europe |
9.2.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
9.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.2.3. Market Opportunity Analysis |
9.3. Asia Pacific (APAC) |
9.3.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
9.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.3.3. Market Opportunity Analysis |
9.4. Middle East and Africa (MEA) |
9.4.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
9.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.4.3. Market Opportunity Analysis |
9.5. Latin America |
9.5.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
9.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.5.3. Market Opportunity Analysis |
10. North America Heparin Market ,2019-2023 and Forecast 2024-2030 (Sales Value USD Million) |
10.1. Product Type Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.1.1.Unfractionated Heparin |
10.1.2.Low Molecular Weight Heparin (LMWH) |
10.1.3.Ultra-low Molecular Weight Heparin (ULMWH) |
10.2. Application Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.2.1.Venous Thromboembolism |
10.2.2.Coronary Artery Disease |
10.2.3.Atrial Fibrillation |
10.2.4.Others |
10.3. Distribution Channel Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.3.1.Hospital Pharmacies |
10.3.2.Drug Stores & Retail Pharmacies |
10.3.3.Online Pharmacies |
10.4. Geography Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.4.1.North America |
10.4.2.Europe |
10.4.3.The Asia Pacific |
10.4.4.Latin America |
10.4.5.MEA |
10.5. Country Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.5.1.United States of America (USA) |
10.5.2.Canada |
11. Europe Heparin Market,2019-2023 and Forecast 2024-2030 (Sales Value USD Million) |
11.1. Product Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.1.1.Unfractionated Heparin |
11.1.2.Low Molecular Weight Heparin (LMWH) |
11.1.3.Ultra-low Molecular Weight Heparin (ULMWH) |
11.2. Application Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.2.1.Venous Thromboembolism |
11.2.2.Coronary Artery Disease |
11.2.3.Atrial Fibrillation |
11.2.4.Others |
11.3. Distribution Channel Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.3.1.Hospital Pharmacies |
11.3.2.Drug Stores & Retail Pharmacies |
11.3.3.Online Pharmacies |
11.4. Geography Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.4.1.North America |
11.4.2.Europe |
11.4.3.The Asia Pacific |
11.4.4.Latin America |
11.4.5.MEA |
11.5. Country Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.5.1.Germany |
11.5.2.France |
11.5.3.Italy |
11.5.4.United Kingdom (UK) |
11.5.5.Spain |
11.5.6.Rest of EU |
12. Asia Pacific (APAC) Heparin Market ,2019-2023 and Forecast 2024-2030 (Sales Value USD Million) |
12.1. Product Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.1.1.Unfractionated Heparin |
12.1.2.Low Molecular Weight Heparin (LMWH) |
12.1.3.Ultra-low Molecular Weight Heparin (ULMWH) |
12.2. Application Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.2.1.Venous Thromboembolism |
12.2.2.Coronary Artery Disease |
12.2.3.Atrial Fibrillation |
12.2.4.Others |
12.3. Distribution Channel Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.3.1.Hospital Pharmacies |
12.3.2.Drug Stores & Retail Pharmacies |
12.3.3.Online Pharmacies |
12.4. Geography Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.4.1.North America |
12.4.2.Europe |
12.4.3.The Asia Pacific |
12.4.4.Latin America |
12.4.5.MEA |
12.5. Country Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.5.1.China |
12.5.2.India |
12.5.3.Australia and New Zealand (ANZ) |
12.5.4.Japan |
12.5.5.Rest of APAC |
13. Middle East and Africa (MEA) Heparin Market ,2019-2023 and Forecast 2024-2030 (Sales Value USD Million) |
13.1. Product Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.1.1.Unfractionated Heparin |
13.1.2.Low Molecular Weight Heparin (LMWH) |
13.1.3.Ultra-low Molecular Weight Heparin (ULMWH) |
13.2. Application Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.2.1.Venous Thromboembolism |
13.2.2.Coronary Artery Disease |
13.2.3.Atrial Fibrillation |
13.2.4.Others |
13.3. Distribution Channel Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.3.1.Hospital Pharmacies |
13.3.2.Drug Stores & Retail Pharmacies |
13.3.3.Online Pharmacies |
13.4. Geography Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.4.1.North America |
13.4.2.Europe |
13.4.3.The Asia Pacific |
13.4.4.Latin America |
13.4.5.MEA |
13.5. Country Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.5.1.GCC Countries |
13.5.2.South Africa |
13.5.3.Rest of MEA |
14. Latin America Heparin Market ,2019-2023 and Forecast 2024-2030 (Sales Value USD Million) |
14.1. Product Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
14.1.1.Unfractionated Heparin |
14.1.2.Low Molecular Weight Heparin (LMWH) |
14.1.3.Ultra-low Molecular Weight Heparin (ULMWH) |
14.2. Application Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
14.2.1.Venous Thromboembolism |
14.2.2.Coronary Artery Disease |
14.2.3.Atrial Fibrillation |
14.2.4.Others |
14.3. Distribution Channel Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
14.3.1.Hospital Pharmacies |
14.3.2.Drug Stores & Retail Pharmacies |
14.3.3.Online Pharmacies |
14.4. Geography Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
14.4.1.North America |
14.4.2.Europe |
14.4.3.The Asia Pacific |
14.4.4.Latin America |
14.4.5.MEA |
14.5. Country Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
14.5.1.Brazil |
14.5.2.Mexico |
14.5.3.Rest of LA |
15. Competition Landscape |
15.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
15.2.1.Baxter International Inc. |
15.2.2.B. Braun Holding GmbH & Co. KG |
15.2.3.Dr Reddy's Laboratories Ltd. |
15.2.4.Fresenius SE & Co KGaA |
15.2.5.Hebei Changshan Biochemical Pharmaceutical Co., Ltd. |
15.2.6.Leo Pharma A/S |
15.2.7.Pfizer Inc. |
15.2.8.Sanofi SA |
15.2.9.Teva Pharmaceuticals |
15.2.10.Viatris Inc. |
16. Research Methodology |
17. Appendix and Abbreviations |
Key Market Players